1 – 10 of 104
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Reflections on the Lancet Commission on Investing in Health's Global Health 2050 report – Authors' reply
- Contribution to journal › Letter
-
Mark
Integrating environmental outcomes in randomised clinical trials : a call to action
- Contribution to journal › Debate/Note/Editorial
-
Mark
Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in patients with intermittent claudication (SWEDEPAD 2) : a multicentre, participant-masked, registry-based, randomised controlled trial
- Contribution to journal › Article
-
Mark
Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1) : a multicentre, participant-masked, registry-based, randomised controlled trial
- Contribution to journal › Article
-
Mark
Epidemiological and demographic trends and projections in global health from 1970 to 2050 : a descriptive analysis from the third Lancet Commission on Investing in Health, Global Health 2050
- Contribution to journal › Article
-
Mark
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH) : a randomised, open-label, phase 2/3 superiority trial
(2025) In The Lancet
- Contribution to journal › Article
-
Mark
Alzheimer's disease outlook : controversies and future directions
- Contribution to journal › Scientific review
-
Mark
New landscape of the diagnosis of Alzheimer's disease
- Contribution to journal › Scientific review
- 2024
-
Mark
First dose of misoprostol administration at home or in hospital for medical abortion between 12–22 gestational weeks in Sweden (PRIMA) : a multicentre, open-label, randomised controlled trial
- Contribution to journal › Article
-
Mark
Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART) : a single-blind, non-inferiority, registry-based, randomised controlled trial
- Contribution to journal › Article
